ACR-ACNM-ASTRO-SNMMI practice parameter for the performance of therapy with radium-223

Mark Hurwitz, John R. Buscombe, Heather A. Jacene, Alan K. Klitzke, Dominick Lamonica, Yang Lu, Daniel A. Pryma, Eric M. Rohren, Tod W. Speer, Rathan M. Subramaniam, Holly M. Thompson, Michael B. Tomblyn, William W. Wong, Ying Xiao, Kevin P. Banks, Richard K.J. Brown

Research output: Contribution to journalArticle

Abstract

Aim/Objectives/Background:The goal of therapy with unsealed radiopharmaceutical sources is to provide either cure or significant prolongation of disease-specific survival, and effective reduction and/or prevention of adverse disease-related symptoms or untoward events while minimizing treatment-associated side effects and complications. Radium-223 dichloride (radium-223) is an alpha particle-emitting isotope used for targeted bone therapy. This practice parameter is intended to guide appropriately trained and licensed physicians performing therapy with radium-223. Such therapy requires close cooperation and communication between the physicians who are responsible for the clinical management of the patient and those who administer radiopharmaceutical therapy and manage the attendant side effects. Adherence to this parameter should help to maximize the efficacious use of radium-223, maintain safe conditions, and ensure compliance with applicable regulations.Methods:This practice parameter was developed according to the process described on the American College of Radiology (ACR) website ("The Process for Developing ACR Practice Parameters and Technical Standards," www.acr.org/ClinicalResources/Practice-Parameters-and-Technical-Standards) by the Committee on Practice Parameters of the ACR Commission on Radiation Oncology in collaboration with the American College of Nuclear Medicine (ACNM), the American Society for Radiation Oncology (ASTRO), and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). All these societies contributed to the development of the practice parameter and approved the final document.Results:This practice parameter addresses the many factors which contribute to appropriate, safe, and effective clinical use of radium-223. Topics addressed include qualifications and responsibilities of personnel, specifications of patient examination and treatment; documentation, radiation safety, quality control/improvement, infection control, and patient education.Conclusions:This practice parameter is intended as a tool to guide clinical use of radium-223 with the goal of facilitating safe and effective medical care based on current knowledge, available resources and patient needs. The sole purpose of this document is to assist practitioners in achieving this objective.

Original languageEnglish (US)
Pages (from-to)539-544
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume43
Issue number8
DOIs
StatePublished - Aug 1 2020

Keywords

  • ACNM
  • ACR
  • ASTRO
  • Radium-223
  • SNMMI
  • practice parameters
  • radiopharmaceutical therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'ACR-ACNM-ASTRO-SNMMI practice parameter for the performance of therapy with radium-223'. Together they form a unique fingerprint.

Cite this